New
Vitiligo drug candidate goes to the finals of The Nature Spinoff Prize
Temprian Therapeutics, a spinoff from Northwestern University with patent for DNA-based vitiligo treatment, has made it to the finals of the Nature Spinoff Prize.
The 12 finalists represent companies from the United States, United Kingdom, Switzerland and Spain operating in pharmaceuticals, predictive assays and medical devices. Temprian’s selection as a finalist for the Nature Spinoff Prize provides hope for securing investment needed for a clinical trial.
The judges will select four companies to participate in a live slam on 13 July. The winner will be awarded the title of 2020 Nature Spin-off Prize champion — and a grant of €30,000 (about US$34,000).
Details of Temprian’s innovation and its underlying patent Mutant HSP70i to Prevent Autoimmune Disease.
FAQOther Questions
- Can Ginkgo Biloba help with vitiligo?
Ginkgo Biloba offers a promising, simple, and relatively affordable option for managing vitiligo. Known for its anti-inflammatory, immunomodulatory, and antioxidant properties, ...
- What joining a clinical trial actually looks like?
Pediatric vitiligo trials · Taking part Cream twice a day, scheduled visits and the practical questions every mother asks before committing the family calendar. The studies disc...
- How can I explain vitiligo to my children?
Vitiligo can be confusing for children because it doesn’t resemble an "illness" in the typical sense. Choosing the right way to explain it depends on your child’s age and maturi...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.